Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct;87(4):526-535.
doi: 10.1111/his.15502. Epub 2025 Jun 25.

Loss of MTAP expression is not an accurate surrogate for CDKN2A homozygous deletions in peritoneal mesothelioma

Affiliations

Loss of MTAP expression is not an accurate surrogate for CDKN2A homozygous deletions in peritoneal mesothelioma

Andrea Quaranta et al. Histopathology. 2025 Oct.

Abstract

Aims: Mesothelioma is a malignant neoplasm of the serosal membranes originating from mesothelial cells. Peritoneal mesothelioma is the second most common mesothelial neoplasm after pleural mesothelioma, accounting for approximately 6%-15% of cases. Due to its high morphological variability, often mimicking other lesions, mesothelioma remains a diagnostic challenge. CDKN2A homozygous deletion has been established as a highly accurate biomarker for differentiating mesothelioma from benign mesothelial proliferations. MTAP immunohistochemistry (IHC) has been proposed as a cheaper and more reproducible surrogate for CDKN2A homozygous deletion (HD) detected by FISH in pleural mesothelioma. The aim of our study was to evaluate the reliability of MTAP IHC as a surrogate marker for CDKN2A HD in peritoneal mesothelioma.

Methods and results: Thirty-nine FFPE tissue samples of PeM were analysed for CDKN2A copy number status by FISH. MTAP IHC was performed using antibody clone 2G4, and cytoplasmic positivity was evaluated using two different cut-offs (1% and 30%). Agreement between IHC and FISH was assessed using Cohen's Kappa. A ROC curve analysis was performed to evaluate the overall diagnostic performance of MTAP IHC. McNemar's test was used to identify statistically significant discordance between the techniques, and a power analysis was conducted to confirm the adequacy of the sample size. Additionally, 14 benign peritoneal lesions were included as external controls and underwent both FISH and IHC. All control samples showed preserved MTAP expression and no CDKN2A deletion. CDKN2A HD was detected in 27/39 cases. MTAP loss was observed in 13 cases, while the remaining 26 cases showed variable levels of MTAP positivity (15%-100%; mean: 36.4%; median: 25%). Cohen's Kappa revealed a low, non-significant concordance between MTAP IHC and CDKN2A HD (cut-off 1%: Kappa = 0.091, P = 0.462; cut-off 30%: Kappa = 0.083, P = 0.326). ROC curve analysis (AUC = 0.569) confirmed the poor discriminatory performance of MTAP IHC. McNemar's test showed a statistically significant discordance between MTAP IHC and CDKN2A FISH results. Power analysis confirmed that the sample size (n = 39) was adequate.

Conclusions: These findings may reflect biological and pathogenetic differences between pleural and peritoneal mesotheliomas. Larger, multicentric studies are needed to validate the diagnostic role of MTAP IHC in peritoneal mesothelioma.

Keywords: CDKN2A; CNV; FISH; MTAP; biomarkers; immunohistochemistry; mesothelioma.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to declare.

Figures

Figure 1
Figure 1
(A) Biphasic peritoneal mesothelioma, H&E. (B) Loss of expression of MTAP in tumour cells together with immunoreactivity in fibroblastic and inflammatory component as internal control. (C) In this case, FISH for CDKN2A did not show a CDKN2A homozygous deletion (green signals highlight locus 9p21 whereas orange signals demonstrate the centromeric probe).
Figure 2
Figure 2
(A) Sarcomatous peritoneal mesothelioma, H&E. (B) Strong cytoplasmic immunoreactivity for MTAP in all tumour cells. (C) In this case, FISH for CDKN2A showed homozygous deletion in over 20% of cells (green signals highlight locus 9p21 whereas orange signals demonstrate the centromeric probe).
Figure 3
Figure 3
(A) Biphasic peritoneal mesothelioma, H&E. (B) Loss of expression of MTAP in almost all the neoplastic cells together with immunoreactivity in the fibroblastic and inflammatory component as internal control. (C) In this case, FISH for CDKN2A showed homozygous deletion in over 20% of cells (green signals highlight locus 9p21 whereas orange signals demonstrate the centromeric probe). [Color figure can be viewed at wileyonlinelibrary.com]
Figure 4
Figure 4
A) Epithelioid peritoneal mesothelioma, H&E. (B) Preserved expression of MTAP in almost all the neoplastic cells together with immunoreactivity in fibroblastic and inflammatory components as internal control. (C) In this case, FISH for CDKN2A did not show homozygous deletion (green signals highlight locus 9p21 whereas orange signals demonstrate the centromeric probe). [Color figure can be viewed at wileyonlinelibrary.com]
Figure 5
Figure 5
ROC curve analysis. AUC = 0.569 indicates that MTAP IHC has limited predictive value for CDKN2A status. [Color figure can be viewed at wileyonlinelibrary.com]

References

    1. Hesdorffer ME, Chabot J, DeRosa C, Taub R. Peritoneal mesothelioma. Curr. Treat. Options in Oncol. 2008; 9; 180–190. - PubMed
    1. Singhi AD, Krasinskas AM, Choudry HA et al. The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma. Mod. Pathol. 2016; 29; 14–24. - PubMed
    1. Chun CP, Song LX, Zhang HP et al. Malignant peritoneal mesothelioma. Am J Med Sci 2023; 365; 99–103. - PubMed
    1. Kim J, Bhagwandin S, Labow DM. Malignant peritoneal mesothelioma: a review. Ann. Transl. Med. 2017; 5; 236. - PMC - PubMed
    1. Malpica A. Peritoneal mesothelioma‐an update. Adv. Anat. Pathol. 2023; 30; 262–274. - PubMed

MeSH terms

Substances

LinkOut - more resources